Steering Committee Meeting May 9, 2016 Congressional Ballroom, Bethesda Marriott Pooks Hill Road

May 10, 2016 Lister Hill Auditorium, NIH Campus

Agenda

Day 1 Monday, May 9, 2016

DURATION	AGENDA TOPIC	WHO	GOAL/DELIVERABLE	
8:00 – 8:15 a.m.	Welcome Opening Remarks	Josephine Briggs Richard Hodes Lesley Curtis	Discussion meeting goals and expectations: The purpose of this meeting is to discuss the progress of the Collaboratory, hear updates from the Core Working Groups and Committees, hear updates and lessons learned from the UH3s, discuss data sharing, and discuss sustainability of the Collaboratory and the generalizable knowledge learned.	
8:15 – 8:45 a.m.	KEYNOTE SPEAKER	Michael Lauer	 Discussion on Perspectives on what should happen outside of the Collaboratory – emphasizing the need for generalizability A 30,000-foot view of clinical trials at NIH and how PCTs fit in 	

DURATION	AGENDA TOPIC	WHO	GOAL/DELIVERABLE
8:45 – 9:15 a.m.	DRN Querying: Use and Sustainability	Lesley Curtis Rich Platt	Discuss planned sustainability and uses of the DRN Discussion on improving the development of data sharing resources (e.g., documentation of how data are generated and coded) to improve the quality of analyses. This may align well with the data warehouse model the NIH is currently considering. Discussion on the expanding the utility of the DRN for current and future UH2/UH3 studies
9:15 – 9:30 a.m.	 Data Governance/Data Sharing Collaboratory principles for data sharing across the Demonstration Projects (5 min) Summary of Data Sharing Policy from Working Group (10 min) 	Adrian Hernandez Greg Simon	Discussion of Collaboratory data sharing principles and policy
9:30 – 10:45 a.m.	Continuation: Data Governance/Data Sharing Final data sharing plans will be provided in the packet, to focus the discussion on the obstacles and replication of analyses. Discuss obstacles related to the final data sharing plan Have your research partners expressed concerns about how the data will be shared (enclave, repository, etc.)? How will individual health systems be identified in shared data sets? Are there legal/regulatory obstacles to sharing your data sets? How/Where will you be sharing your results? Can the analysis be replicated	Moderator: Adrian Hernandez Greg Simon Susan Huang Jerry Jarvik Laura Dember Lynn DeBar Gloria Coronado	Discussion of final data sharing plans for the first group of UH3s: how and where data will be shared, any foreseen obstacles, and replication of analyses
10:45 – 11:00 a.m.	using the shared data sets? Break		

DURATION	AGENDA TOPIC	WHO	GOAL/DELIVERABLE
11:00 – 12:00 p.m.	Continuation: Data Governance/Data Sharing Data sharing plans will be provided in the packet, to focus the obstacles and implementation of the Collaboratory policy.	Moderator: Adrian Hernandez	Discussion about the current data sharing plans for the MCC UH3s, what will be shared, and any foreseen obstacles with current data sharing plans
	 What is your current data sharing plan and do you foresee any obstacles? What information did the IRB require about how the data would be shared beyond the study in order to waive informed consent? How will you put the policy from the data sharing work group into practice in your study? What data are you planning to share from your project (individual-level data, group-level data, specific variables/outcomes, etc.)? 	Doug Zatzick Vincent Mor Miguel Vazquez/ George (Holt) Oliver	
12:00 – 12:30 p.m.	ICD-10 Transition	Rachel Richesson	Discussion on how the transition of ICD-9 to ICD-10 will affect the Demonstration Projects, and in general, what it means for PCTs
12:30 – 1:00 p.m.	Lunch		
1:00 – 1:45 p.m.	Biostatistics and Study Design	Liz DeLong David Murray	Discussion on exploring techniques to anticipate changes in the control group. This is a major challenge for PCTs. Approaches such as steppedwedge design, adaptive interventions/smart design, and adaptive designs are options. Small strategic ancillary studies may help investigators measure mediators without complicating PCT designs.
1:45 – 2:15 p.m.	Results Reporting for PCTs	Kevin Weinfurt	Discussion of what information should be reported in a PCT results publication, including details about the health systems data and analytic methods used

DURATION	AGENDA TOPIC	WHO	GOAL/DELIVERABLE
2:15 – 2:30 p.m.	Discussion from the Following Core Groups: Stakeholder Engagement Healthcare Systems Interactions	Rachael Moloney Eric Larson / Leah Tuzzio	Discussion on generalizable knowledge created out of the Cores, how it can be utilized, and future work of the Cores Provide lessons learned from the Demonstration Projects Provide update on Core activities on sustainability for the Demonstration Projects
2:30 – 3:00 p.m.	Training/Mentoring the Next Generation of Researchers	Adrian Hernandez	Discuss how to change the next generation of researchers and models to help educate people on PCTs
3:00 – 3:15 p.m.	Break		
3:15 – 4:30 p.m.	Generalizable Lessons Learned and Sustainability from the Demonstration Projects 10 min per project 15 min discussion		Project abstracts in the meeting materials. Presentation to focus on generalizable lessons learned and on how the Demonstration Projects are planning for sustainability
	Collaborative Care for Chronic Pain in Primary Care (PPACT)	Lynn DeBar	Updated look at the Barriers Score Card from the first group of UH3 Projects
	Strategies and Opportunities to Stop Colon Cancer in Priority Populations (STOP CRC)	Gloria Coronado	
	Active Bathing to Eliminate (ABATE) Infection	Susan Huang	
	Lumbar Imaging with Reporting of Epidemiology (LIRE)	Jerry Jarvik	
	Time to Reduce Mortality in End-Stage Renal Disease (TiME)	Laura Dember	
	Suicide Prevention Outreach Trial (SPOT)	Greg Simon	

DURATION	AGENDA TOPIC	WHO	GOAL/DELIVERABLE
4:30 – 5:15 p.m.	Generalizable Lessons Learned and Sustainability from the Demonstration Projects 10 min per project 15 min discussion • A Policy-Relevant U.S.	Doug Zatzick	Project abstracts in the meeting materials. Presentation to focus on overall lessons learned from the UH2 planning phase of the study, sustainability for the UH3 implementation phase, and any challenges Identify the issues/challenges utilizing the Barriers Score Card from the
	Trauma Care System Pragmatic Trial for PTSD and Comorbidity (Trauma Survivors Outcomes and Support [TSOS]) Improving Chronic Disease Management with Pieces (ICD-Pieces™)	Miguel Vazquez	MCC UH3s Additional questions to consider for discussion: Are there any special considerations that should be considered when designing a Multiple Chronic Condition PCT?
	Pragmatic Trial of Video Education in Nursing Homes (PROVEN) Pragmatic Trial of Video Education in Nursing Homes (PROVEN)	Vincent Mor	 Was the UH2 planning period useful—what did it allow you to do? What worked/didn't work about the UH2 phase? Were the milestones for the UH2 phase appropriate and clear enough? What changes would you recommend about the UH2 phase and transition? How has the Coordinating Center assisted your project? What could the Coordinating Center have done to provide more assistance? Feedback on the UH3 transition process: information letter to PIs, review criteria, submission
5:15 – 5:45 p.m.	Living Textbook	Kevin Weinfurt Jonathan McCall Gina Uhlenbrauck Karen Staman	process, and approval process Discussion about the restructure of the Living Textbook and the sustainability of the resource
5:45 – 6:00 p.m.	Closing Remarks/Adjourn	Josephine Briggs Richard Hodes Lesley Curtis	Summarize the meeting

DAY 2 TUESDAY, MAY 10, 2016

Ethical and Regulatory Issues of Pragmatic Clinical Trials Workshop Lister Hill Auditorium, NIH Campus

DURATION	AGENDA TOPIC	WHO	GOAL/DELIVERABLE
8:00 – 8:10 a.m.	Welcome and Introduction	Josephine Briggs Catherine Meyers Wendy Weber	Discuss the overall meeting goals and objectives: The workshop aims to inform research funders and investigators on progress with navigating ongoing ethical and regulatory challenges for pragmatic clinical trial (PCT) research. Describe the unique challenges PCTs face in the current ethical and regulatory environment Provide strategies to address some of these challenges from
8:10 – 8:30 a.m.	KEYNOTE SPEAKER	Jeremy Sugarman	ongoing PCTs Identify available and needed resources to assist PCT research funders and investigators to address ethical and regulatory requirements Discuss the overall landscape of the
6.10 – 6.30 a.m.	RETNOTE SPEAKER	Jeremy Sugarman	ethical and regulatory issues facing PCTs
8:30 – 10:15 a.m.	Options for Altered Consent and the Importance of Minimal Risk Determination • Moderator Summary • Q&A	Moderator: Kevin Weinfurt <u>Panel</u> : Laura Dember	A moderated discussion using case examples from the Collaboratory to focus on options for altered consent and the importance of minimal risk determination for PCTs
		Gregory Simon John Lantos Emma Meagher	
10:15 – 10:30 a.m.	Break		

DAY 2 TUESDAY, MAY 10, 2016

Ethical and Regulatory Issues of Pragmatic Clinical Trials Workshop Lister Hill Auditorium, NIH Campus

DURATION	AGENDA TOPIC	WHO	GOAL/DELIVERABLE	
10:30 – 12:15 p.m.	Oversight of Pragmatic Clinical Trials – Institutional Review Boards and Data & Safety Monitoring Boards	Moderator: Adrian Hernandez <u>Panel</u> :	A moderated discussion using case examples from the Collaboratory to focus on issues in the oversight of PCTs by institutional review boards and data & safety monitoring boards	
	Moderator SummaryQ&A	Douglas Zatzick		
	• QaA	Pearl O'Rourke		
		Susan Ellenberg		
12:15 – 1:15 p.m.	Lunch			
1:15 – 2:00 p.m.	Privacy Issues for Pragmatic Clinical Trials	Moderator:	A moderated discussion using case	
	Chilical Itials	Valerie Bonham	examples from the Collaboratory to focus on the privacy issues for PCTs	
	Moderator Summary	<u>Introduction</u> :		
	• Q&A	Sarah Greene		
		<u>Panel:</u>		
		Valery Gordon		
		Miguel Vazquez		
2:00 – 2:45 p.m.	Vulnerable PopulationsModerator SummaryQ&A	Moderator: David Wendler <u>Panel</u> :	A moderated discussion using case examples from the Collaboratory to focus on issues regarding the inclusion of vulnerable populations in PCTs	
		Susan Huang		
		Mary Jane Welch		
2:45 – 3:00 p.m.	Break			
3:00 – 4:00 p.m.	Expert Panel Q&A	Moderator: Jeremy Sugarman	Provide an opportunity for Q&A on the ethical and regulatory issues facing PCTs. Focus discussion on the objectives of the meeting:	
		Panel: Kevin Weinfurt Adrian Hernandez Valerie Bonham David Wendler	 Describe the unique challenges PCTs face in the current ethical and regulatory environment Provide strategies to address some of these challenges from ongoing PCTs 	
		David Welldiel	Identify available and needed resources to assist PCT research funders and investigators to address ethical and regulatory requirements	
4:00 p.m.	Concluding Remarks	Michael Lauer	Summarize the meeting	